Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (985)	4/21/2001 9:32:43 PM
From: Miljenko Zuanic	Respond to of 3158

If pharma can do it (for now only rumor), what is so difficult for bios? I will first reduce (in third) options vesting period, reduced options and fat bonuses award. So, they may change their broken record tomorrow, or the sooner the better. Miljenko Saturday April 21, 5:33 pm Eastern Time GlaxoSmithKline seen eyeing U.S. drugs firm-paper LONDON, April 21 (Reuters) - British pharmaceuticals giant GlaxoSmithKline (quote from Yahoo! UK & Ireland: GSK.L) is considering starting talks about a 150 billion pound ($216.5 billion) merger with U.S. drugs firm American Home Products Corp (NYSE:AHP - news), a newspaper reported on Sunday. Britain's Sunday Observer quoted GSK ``company insiders'' as saying that the company's Chief Executive Jean-Pierre Garnier had charged a high-level task force with finding targets and AHP was Garnier's favoured U.S. target for his next big deal. GSK spokesman Martin Sutton told Reuters when asked about the report: ``We never comment on rumour and speculation.'' Industry sources said they were sceptical that such a deal was imminent as GSK still had enough to deal with after the merger between Glaxo Wellcome and SmithKline Beecham that formed GSK at the end of last year. Garnier said in February that GlaxoSmithKline was ready to make acquisitions to build the drugmaker's pipeline of new products. An earlier attempt to merge AHP with SmithKline Beecham, before the deal forming GSK, failed. ``Garnier still admires AHP greatly from his SmithKline days,'' one GSK insider was quoted by the Observer as saying. ``The two fit like a glove, strong in vaccines and consumer products. AHP also has a good new drugs pipeline while Glaxo and SmithKline's have been relatively weak,'' the insider added.